G. Di Perri

Durability of different initial regimens in HIV-infected patients starting antiretroviral therapy with CD4+ counts <200 cells/mm3 and HIV-RNA >5 log10 copies/mL.

A. d’Arminio Monforte, F. Ceccherini‐Silberstein, G. Ippolito, 2019, The Journal of antimicrobial chemotherapy.

NNRTIs: future prospects.

P. Dellamonica, R. Garraffo, G. Di Perri, 2012, Medecine et maladies infectieuses.

Vitamin D status in the extreme age of life.

G. Di Cairano, F. Loré, G. Di Perri, 1986, Annales de medecine interne.

Incidence and risk factors for liver enzyme elevation among naive HIV-1-infected patients receiving ART in the ICONA cohort.

A. d’Arminio Monforte, F. Ceccherini‐Silberstein, G. Ippolito, 2019, The Journal of antimicrobial chemotherapy.

Pre-ART HIV-1 DNA in CD4+ T cells correlates with baseline viro-immunological status and outcome in patients under first-line ART

A. d’Arminio Monforte, F. Ceccherini‐Silberstein, G. Ippolito, 2018, The Journal of antimicrobial chemotherapy.

NNRTIs: pharmacological data.

P. Dellamonica, R. Garraffo, G. Di Perri, 2012, Medecine et maladies infectieuses.

Concomitant Use of an Active Boosted Protease Inhibitor with Enfuvirtide in Treatment-Experienced, HIV-Infected Individuals: Recent Data and Consensus Recommendations

A. Blaxhult, B. Clotet, C. Kovacs, 2006, HIV clinical trials.